Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Withdrawn 8Not yet recruiting 4Completed 4Recruiting 3Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × ALT-803 × Clear all
NCT07574541 2026-06-05

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT07355205 2026-05-22

FLINN

Washington University School of Medicine

Phase 2 Not yet recruiting
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

ImmunityBio, Inc.

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

ImmunityBio, Inc.

Phase 2 Not yet recruiting
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡